Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
Getnet Teshome,1 Sintayehu Ambachew,2 Alebachew Fasil,2 Molla Abebe2 1University of Gondar Comprehensive Specialized Hospital, University of Gondar, Gondar, Amhara, Ethiopia; 2Department of Clinical Chemistry, University of Gondar, Gondar, Amhara, EthiopiaCorrespondence: Getnet TeshomeUniversity of...
Main Authors: | Teshome G, Ambachew S, Fasil A, Abebe M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-09-01
|
Series: | Hepatic Medicine: Evidence and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/efficacy-of-glucagon-like-peptide-1-analogs-in-nonalcoholic-fatty-live-peer-reviewed-article-HMER |
Similar Items
-
The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
by: Ana Petrovic, et al.
Published: (2023-05-01) -
Glucagon‐like peptide agonists: A prospective review
by: Zamara Mariam, et al.
Published: (2024-01-01) -
Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Magdalena Mazurek, et al.
Published: (2023-02-01) -
One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
by: Louise Vedtofte, et al.
Published: (2020-10-01) -
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment
by: Stefano Ciardullo, et al.
Published: (2023-08-01)